

**How to Cite:**

Alanazi, H. H. F., Alqarni, A. M. S., Almalki, M. H. M., Alamri, A. A. H., Alghamdi, A. S., Alotaibi, M. S. A., Al Nemer, A. A. R., Alharbi, S. O. S., Alqahtani, S. F. M., Halawani, A. Z., Alharbi, M. A., Alkhuraym, Y. Y., Alharthi, A. H., Alsawaji, M., Almotairi, B. A., Al-Anzi, S. K., Al-Anzi, F. A., & Al-Anzi, M. A. (2024). Dealing with Lupus (SLE) and nursing intervention plan: An updated review. *International Journal of Health Sciences*, 8(S1), 1734–1758. <https://doi.org/10.53730/ijhs.v8nS1.15388>

## **Dealing with Lupus (SLE) and nursing intervention plan: An updated review**

**Hamad Huran F Alanazi**

Ministry of National Guard Health Affairs

**Ali Mohammed S Alqarni**

Ministry of National Guard Health Affairs

**Mesfer Hamed M Almalki**

Ministry of National Guard Health Affairs

**Abdullah Abdulqader H Alamri**

Ministry of National Guard Health Affairs

**Abdulaziz Saad Alghamdi**

Ministry of National Guard Health Affairs

**Manal Saad Aied Alotaibi**

Ministry of National Guard Health Affairs

**Azzam Abdullah Rashed Al Nemer**

Ministry of National Guard Health Affairs

**Sultan Obaid Salem Alharbi**

Ministry of National Guard Health Affairs

**Salem Faraj M Alqahtani**

Ministry of National Guard Health Affairs

**Abdulrhman Zaher Halawani**

Ministry of National Guard Health Affairs

**Mohammed Ali Alharbi**

Ministry of National Guard Health Affairs

**Yousef Yahya Alkhuraym**

Ministry of National Guard Health Affairs

**Ahmad Hassan Alharthi**

Ministry of National Guard Health Affairs

**Majed Alsawaji**

Ministry of National Guard Health Affairs

**Bunaydir Aali Almotairi**

Ministry of National Guard Health Affairs

**Sami Khaled Al-Anzi**

Medicine and Emergen, Armed Forces Hospital in the Northern Region

**Faris Abdullah Al-Anzi**

Medicine and Emergen, Armed Forces Hospital in the Northern Region

**Mishaal Atiq Al-Anzi**

Medicine and Emergen, Armed Forces Hospital in the Northern Region

**Abstract--Background:** Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by periodic flare-ups and remissions, causing multi-organ damage. It is marked by the production of autoantibodies that lead to inflammation and tissue injury. While advances have been made in understanding SLE's pathogenesis, treatments continue to rely on broad immunosuppressive therapies, with more targeted therapies emerging as promising options. This review explores the mechanisms behind SLE and evaluates current and future therapeutic strategies. **Aim:** This review aims to provide an updated overview of the pathogenesis of SLE, recent advances in diagnostic approaches, and the development of targeted treatments, focusing on the potential for personalized therapy. **Methods:** The review synthesizes recent literature on SLE epidemiology, pathogenesis, diagnostic criteria, and therapeutic advancements. It explores the roles of adaptive and innate immunity, mitochondrial dysfunction, apoptosis, and interferon involvement in disease progression. **Results:** SLE's pathogenesis involves dysregulated immune responses, with significant contributions from B and T lymphocytes, type-I interferon (IFN) production, neutrophil dysfunction, and mitochondrial abnormalities. Advances in diagnostic tools, including anti-dsDNA and anti-ENA antibodies, have improved disease identification. Therapeutic strategies now include both traditional immunosuppressive treatments and newer targeted therapies aimed at specific immune pathways, with the goal of reducing reliance on broad immunosuppressants. **Conclusion:** SLE remains a complex, multifactorial disease, with advancements in understanding its pathogenesis leading to promising therapeutic innovations. Targeted therapies and personalized treatment strategies are poised to significantly improve patient outcomes. However, challenges remain in

optimizing treatment approaches and addressing disease variability across different populations.

**Keywords**---Systemic lupus erythematosus, autoimmune disease, pathogenesis, targeted therapies, immune system, mitochondria, interferon, B cells, T cells, lupus nephritis.

## **Introduction**

Systemic lupus erythematosus (SLE) is a complex autoimmune condition marked by alternating periods of flare-ups and remission, causing significant damage to various organs and tissues. The kidneys, nervous system, joints, and skin are the most frequently affected. A defining characteristic of SLE is the production of circulating autoantibodies that form immune complexes, precipitating in blood vessels and triggering potent inflammatory responses responsible for multi-organ damage [1,2]. Advances in understanding SLE pathogenesis over recent decades have highlighted the dysregulation of both innate and adaptive immune systems, with type-I interferon (IFN) playing a central role. This cytokine induces the overactivation of pro-inflammatory gene expression, a phenomenon referred to as the type-I IFN signature [3]. Despite therapy for SLE still relying on nonspecific immunosuppressive and immunomodulatory drugs [4], targeted therapies focusing on specific immune pathways have recently emerged, with some receiving regulatory approval [5]. However, these newer treatments often require combination with traditional therapies to achieve satisfactory disease control. This review delves into recent advancements in understanding SLE mechanisms, the therapeutic potential of current targeted drugs, and prospects for personalized therapies aimed at minimizing reliance on conventional treatments.

## **Epidemiology**

The global incidence and prevalence of SLE have risen in recent decades, attributed to improved diagnostic techniques and comprehensive international registry data. The estimated incidence of SLE varies significantly by region, ranging from 0.3 to 23.2 cases per 100,000 person-years [6]. North America reports the highest incidence, while sub-Saharan Africa, Europe, and Australia exhibit lower rates, influenced by genetic predisposition [7], socioeconomic factors [8], and environmental conditions [9]. Women of reproductive age are disproportionately affected, with female-to-male incidence ratios between 8:1 and 15:1 [9]. Among ethnic groups, African Americans have the highest SLE incidence and mortality, followed by Hispanic and Asian populations, whereas Caucasians show the lowest rates [10]. African populations, however, display greater susceptibility to SLE and reduced responsiveness to systemic treatments such as corticosteroids and immunosuppressants [11]. Overall, SLE patients face a mortality risk approximately 2.6 times higher than the general population [12], with delayed diagnosis, renal complications, heightened disease activity, infections, and major cardiovascular events identified as primary mortality predictors [11].

## **Diagnosis, Management, and Disease Activity Criteria for SLE**

According to the 2019 classification criteria from the European Alliance of Associations for Rheumatology (EULAR) and the American College of Rheumatology (ACR), a positive antinuclear antibody (ANA) test is required as an entry criterion for SLE diagnosis [5]. However, ANA presence is not exclusive to SLE and may be detected in healthy individuals and other autoimmune or non-autoimmune disorders [13,14,15]. Furthermore, approximately 30% of clinically diagnosed SLE patients are ANA-negative [16]. The anti-dsDNA antibody is considered diagnostic for SLE and is strongly correlated with disease activity [17]. Anti-extractable nuclear antigen (ENA) antibodies, particularly anti-Sm antibodies, are more specific markers for SLE. These are often found alongside anti-U1-ribonucleoprotein (U1-RNP) antibodies, which bind small nuclear ribonucleoproteins (snRNP) and are characteristic of mixed connective tissue disease [18]. Anti-SSA and anti-SSB antibodies, common in Sjögren's syndrome, appear in 24–60% of SLE cases and are associated with neonatal lupus [19]. Anti-histone antibodies are indicative of drug-induced lupus, while anti-ribosomal antibodies are linked to the disease itself. Antiphospholipid antibodies, including lupus anticoagulant, anti-cardiolipin, and anti- $\beta$ 2 glycoprotein 1, serve as markers for vascular inflammation and thromboembolic risk, and are implicated in recurrent pregnancy loss, thrombosis, and neurovascular complications [20,21]. The diagnostic process requires a cumulative score of at least ten points from clinical and immunological domains, with the criteria demonstrating 96.1% sensitivity and 93.4% specificity [22]. Continuous monitoring and evaluation are crucial for the long-term management of SLE patients. Assessing disease activity poses challenges due to the multisystem nature of SLE. The SLE Disease Activity Index-2K (SLEDAI-2K) is the most widely used tool, categorizing disease severity with scores ranging from  $\leq 6$  for mild to  $\geq 12$  for severe cases [24]. The 2004 British Isles Lupus Activity Group (BILAG) index, which evaluates eight organ systems, offers a more comprehensive systems-based measure [25]. For organ damage evaluation, the internationally recognized Systemic Lupus International Collaborating Clinics (SLICC)/ACR Damage Index (SDI) is frequently utilized [26]. Clinical trials often rely on the SLE Responder Index (SRI), which integrates criteria from SELENA-SLEDAI, Physician Global Assessment (PGA), and BILAG 2004 [27].

## **Pathogenesis of Systemic Lupus Erythematosus (SLE)**

### **Role of Adaptive Immunity**

B lymphocytes, distinguished by the presence of B-cell receptors (BCRs) on their surface, are essential for identifying pathogens and generating specific antibodies [28]. However, during B-cell development, autoreactive B cells may emerge. Although mechanisms of immunological tolerance, such as clonal deletion and peripheral anergy, typically regulate these cells, these systems can fail, leading to the expansion and activation of autoreactive B cells and potentially triggering autoimmune diseases [29,30,31]. The survival and proliferation of B cells, including self-reactive ones, rely on soluble factors, particularly the B-cell activating factor (BAFF), also termed B lymphocyte stimulator (BLyS) [32,33]. Autoreactive B cells predominantly produce autoantibodies targeting nuclear antigens. Toll-like receptors (TLRs), particularly TLR7 and TLR9, play a pivotal

role in this process, driving the production of autoantibodies against double-stranded DNA (dsDNA) and RNA-associated antigens in SLE [34–37]. Long-lived plasma cells (LLPCs), derived from terminally differentiated B cells, are major contributors to sustained autoantibody production. Interaction with CD4<sup>+</sup> T cells in lymph node germinal centers transforms short-lived plasmablasts into high-affinity plasma cells, which migrate to bone marrow niches, ensuring their longevity and continued autoantibody secretion [38]. Spontaneous germinal center formation, observed in murine and human SLE, underscores its critical role in autoantibody generation [39]. Additionally, B cells can act as antigen-presenting cells (APCs) to autoreactive T lymphocytes, as evidenced in mouse models [40,41].

The pathogenic role of autoantibodies remains a debated subject. Although autoantibodies can be detected years before clinical manifestations of SLE, suggesting their utility as biomarkers, substantial evidence supports their role in disease progression. For instance, immune complexes in lupus nephritis, comprising autoantibodies such as anti-dsDNA antibodies, contribute to glomerular pathology; their removal is associated with disease improvement [42–44]. Moreover, neonatal lupus erythematosus (NLE) arises from passive transfer of maternal autoantibodies, emphasizing their role in SLE pathogenesis [45]. Thus, autoantibodies are implicated in the clinical manifestations of SLE to a significant extent. Self-reactive T cells are central to SLE development. T-helper 1 (Th1) cells exacerbate SLE through oxidative stress mediated by interferon-gamma (IFN $\gamma$ ) production [46]. Conversely, IL-4-producing T-helper 2 (Th2) cells are reduced in SLE patients, suggesting their protective role and linking disease activity to an increased IFN $\gamma$ /IL-4 ratio [47]. T-helper 17 (Th17) cells, major producers of the pro-inflammatory cytokine IL-17, also contribute to SLE by inducing neutrophil recruitment, innate immune activation, and B-cell enhancement [48]. Elevated IL-17 levels correlate with lupus nephritis severity and disease activity [49,50]. Regulatory T cells (Tregs) maintain peripheral tolerance to self-antigens, but their role in SLE remains controversial due to conflicting findings. However, Tregs' ability to suppress effector T cells suggests their potential in SLE cell therapy [51–53]. T-follicular helper (Tfh) cells facilitate autoreactive B-cell clone generation in germinal centers, contributing to lupus nephritis through localized aggregation with B cells [54,55]. Interactions between CD4<sup>+</sup> T cells and B cells are vital in sustaining autoimmunity, promoting autoreactive B-cell survival and differentiation into autoantibody-producing plasma cells. CD8<sup>+</sup> T cells are also implicated in SLE immunopathogenesis, exhibiting functional impairments such as reduced cytolytic activity due to diminished granzyme and perforin production [56]. This phenotype correlates with lower disease flare rates but increases infection susceptibility, compounded by immunosuppressive therapies [57,58]. Finally, the elevated presence of  $\gamma\delta$ -T lymphocytes in SLE patients highlights their role in autoimmunity [59,60].

### **Role of Innate Immunity**

Neutrophils in SLE exhibit significant dysfunction, including impaired phagocytosis and defective clearance of apoptotic cells, which serve as sources of autoantigens [61–63]. Genetic variations in ITGAM, NCF1, and NCF2 exacerbate these dysfunctions by disrupting phagocytosis and reactive oxygen species (ROS)

regulation [64–66]. Furthermore, neutrophils contribute to abnormal B-cell development through type-I interferon (IFN-I) production, independent of TLR stimulation [67,68]. Low-density granulocytes (LDGs), a subtype of neutrophils enriched in SLE patients, are associated with IFN signature and disease severity. LDGs also exhibit heightened neutrophil extracellular trap (NET) formation, contributing to autoantigen exposure and endothelial damage via ROS [69–73]. Genetic polymorphisms promoting increased NET formation further amplify inflammasome activation in macrophages, driving inflammatory responses [74–78]. Plasmacytoid dendritic cells (pDCs), key producers of IFN-I, are integral to SLE pathogenesis [79–81]. pDCs internalize circulating nucleic acids via FcγRIIIa and activate TLR7 and TLR9 pathways, triggering Myd88- and IRAK4-mediated signaling cascades for IFN-I production [82–85]. This production links innate and adaptive immunity by promoting extrafollicular B-cell differentiation into plasmablasts and activating pro-inflammatory T cells, thereby exacerbating SLE [86–89]. Despite their pathogenic role, pDCs also have tolerogenic functions, inducing regulatory T cells (Tregs) and IL-10-producing regulatory B cells (Bregs), which suppress IFN-I production. Dysregulation of this feedback loop is a pivotal factor in SLE development, making pDCs a potential target for therapeutic intervention [90–93].

### **The Role of Mitochondria**

Mitochondria, essential organelles for energy production, generate ATP vital for cell metabolism. During apoptosis, damaged mitochondria release mitochondrial DNA (mtDNA), which is unstable and prone to degradation into antigenic fragments. MtDNA can activate autoreactive T cells in SLE, subsequently stimulating B cells to produce anti-DNA antibodies. Resembling bacterial DNA, mtDNA can also engage toll-like receptors (TLRs), eliciting inflammatory responses such as type-I interferon (IFN) production, contributing to immune tolerance breakdown. Additionally, mitochondrial genetic variants linked to SLE increase oxidative stress, as evidenced by oxidized mtDNA accumulation in neutrophils of affected individuals. During NETosis, oxidized mtDNA may trigger type-I IFN production through plasmacytoid dendritic cells. Furthermore, mitochondrial RNA (mtRNA) serves as another autoantigen, with higher autoantibody levels against mtRNA observed in SLE patients [94-104].

### **The Role of Apoptosis**

Apoptosis, crucial for removing cellular debris and maintaining immune tolerance, relies on nucleases for nucleic acid digestion. Deficiencies in these enzymes, such as DNASE1L3 or TREX1, lead to lupus-like symptoms in animal models. In SLE, impaired apoptotic clearance results in undigested DNA accumulation, immune complex formation, and autoimmune responses. Pattern recognition receptor (PRR) activation by apoptotic remnants exacerbates this defect. Studies confirm that SLE patients exhibit reduced efficiency in apoptotic cell clearance. Furthermore, neutrophil extracellular traps (NETs) complicate the digestion of DNA, promoting type-I IFN secretion by plasmacytoid dendritic cells [105-118].

## **The Role of Interferons in SLE**

Type-I IFN plays a pivotal role in SLE pathogenesis. IFN $\alpha$  and IFN $\beta$  are key drivers, activated by PRRs such as toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG-I). Plasmacytoid dendritic cells, significant producers of type-I IFN, trigger downstream signaling via the IFN $\alpha$  receptor (IFNAR), leading to an inflammatory cascade mediated by JAK1, TYK2, and STAT transcription factors. This pathway induces genes that amplify inflammation. Observations in patients treated with IFN $\alpha$  for other conditions demonstrate a direct link between IFN exposure and lupus-like symptoms, which often resolve upon discontinuation of therapy. Genetic polymorphisms in IFN signaling components, such as STAT and IRF genes, further underscore the genetic predisposition to SLE. Additionally, the IFN signature is emerging as a potential biomarker for tailoring anti-IFN therapies. This intricate interplay between mitochondria, apoptotic pathways, and interferon signaling highlights their collective contribution to SLE's complex etiology and presents avenues for targeted therapeutic interventions [119-138].

## **SLE Treatment**

### **The EULAR/ACR Recommendations**

Systemic lupus erythematosus (SLE) treatment has yet to replace traditional therapies decisively, according to the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Their guidelines emphasize achieving remission or low disease activity using the "treat-to-target" approach adapted from rheumatoid arthritis management [4, 139, 140, 141]. Hydroxychloroquine (HCQ) is widely recommended for all SLE patients due to its long-term safety, ability to prevent flares, and low cost, making it particularly viable in low-income regions. Its dosage is limited to 5 mg/kg body weight to avoid retinal complications [142, 143, 144]. Glucocorticoid usage is recommended at doses below 7.5 mg/day, or their complete discontinuation if possible, due to risks such as osteoporosis, diabetes, and infection [145]. Immunosuppressants like azathioprine, methotrexate, mycophenolate mofetil, and cyclophosphamide (CYC) serve as steroid-sparing agents, but their application is limited by side effects, including teratogenic risks with mycophenolate and cancer risks with CYC [146, 147, 148]. These considerations necessitate combining innovative biologics with conventional therapies when standard treatments are insufficient [149].

### **Rituximab**

Rituximab, a monoclonal antibody targeting CD20 for B-cell depletion, has theoretical benefits in SLE. However, the EXPLORER and LUNAR trials failed to meet their endpoints due to flawed designs and incomplete depletion of tissue-resident CD20+ B cells [150, 151, 152]. Further analyses revealed benefits, such as reduced proteinuria in lupus nephritis (LN) and clinical improvements in African American and Hispanic subgroups [150, 151]. Innovative anti-CD20 agents, like obinutuzumab, show promise for more effective B-cell depletion and improved renal response in LN, though infection risks remain a concern [156, 157, 158].

### **Belimumab**

Belimumab, an anti-BAFF monoclonal antibody, gained FDA approval in 2011 for moderate to severe SLE in adults and was later approved for pediatric use and LN treatment. The BLISS-52 and BLISS-76 trials demonstrated statistically significant benefits of belimumab in combination with standard therapy, particularly for patients with high disease activity [159, 160, 161]. Subcutaneous administration proved effective in the BLISS-SC study, leading to its approval in 2017 [165]. In LN, the BLISS-LN trial showed improved primary and complete renal responses with belimumab compared to placebo, confirming its kidney-preserving effects [167, 168].

### **Anifrolumab**

Anifrolumab, an anti-type-I interferon (IFN) receptor monoclonal antibody, is approved for moderate to severe SLE at 300 mg every four weeks. Its efficacy was established through the MUSE trial and two phase III TULIP studies. Although TULIP-1 failed to meet its primary endpoint, a protocol modification in TULIP-2 to focus on BILAG-based composite lupus assessment (BICLA) criteria led to successful outcomes, including reduced disease relapse and glucocorticoid use [169, 170, 171]. Pooled analyses confirmed anifrolumab's efficacy, particularly in patients with high type-I IFN signatures, making it a valuable addition to SLE management [173, 174].

### **Nursing Interventions for Systemic Lupus Erythematosus (SLE)**

Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disorder that involves inflammation of various organ systems. Effective nursing interventions in SLE aim to manage symptoms, prevent complications, and improve the patient's overall quality of life. These interventions are multifaceted, focusing on education, symptom management, psychosocial support, and collaboration with interdisciplinary teams to provide comprehensive care.

#### **Patient Education and Self-Management**

A cornerstone of nursing interventions in SLE is patient education. Nurses play a vital role in ensuring that patients understand the nature of their condition, the treatment regimen, and strategies for managing symptoms. First and foremost, nurses should educate patients on the importance of medication adherence. Medications commonly prescribed for SLE, such as hydroxychloroquine, corticosteroids, and immunosuppressants, can have significant side effects and require consistent use to maintain disease control. Nurses must ensure that patients are aware of potential side effects, such as retinal toxicity from hydroxychloroquine or increased susceptibility to infections from immunosuppressive therapies, and emphasize the importance of regular follow-up appointments to monitor these effects. Additionally, patient education should address the avoidance of disease triggers, particularly ultraviolet (UV) light, which can exacerbate symptoms. Nurses can advise patients to use sunscreen and wear protective clothing to limit UV exposure. Furthermore, promoting a healthy lifestyle is essential; nurses should encourage balanced nutrition, regular

exercise, and smoking cessation, as smoking has been shown to worsen the symptoms of SLE and reduce the effectiveness of treatment.

### **Symptom Monitoring and Management**

Symptom management is central to nursing care for SLE patients. Nurses must conduct regular assessments to monitor disease activity and ensure early intervention when symptoms worsen. Key symptoms to monitor include fatigue, joint pain, skin rashes, and systemic involvement such as renal or cardiovascular issues. Using validated tools like the SLE Disease Activity Index (SLEDAI), nurses can objectively assess disease activity and track changes over time. Pain management is often a significant concern for patients with SLE, especially those experiencing arthritis or musculoskeletal discomfort. Nurses are responsible for administering prescribed analgesics and recommending complementary therapies such as heat or cold applications, and physical therapy, to manage pain and improve mobility. Furthermore, nurses must monitor for signs of organ damage, particularly renal involvement, which is common in SLE patients. Regular screening for proteinuria, blood pressure monitoring, and assessing for signs of lupus nephritis are essential components of care. Early detection and management of organ damage are critical to preventing irreversible damage and improving long-term outcomes.

### **Psychosocial Support**

Living with a chronic, unpredictable disease such as SLE can take a toll on a patient's mental and emotional well-being. Therefore, nursing interventions must also address the psychosocial aspects of the disease. Nurses should provide emotional support by creating a safe and supportive environment for patients to express their concerns. Active listening and empathetic communication are essential in fostering trust and alleviating feelings of isolation. Nurses should be proactive in referring patients to counseling services if they experience significant emotional distress, anxiety, or depression. Cognitive-behavioral therapy (CBT) has proven effective in helping patients develop coping mechanisms for dealing with the chronic nature of their illness. Additionally, connecting patients with support groups can provide valuable social interaction and an opportunity for patients to share experiences with others facing similar challenges. These peer interactions often lead to a sense of empowerment and emotional resilience, which are critical for managing a chronic illness.

### **Preventing and Managing Complications**

SLE is associated with a range of potential complications, including cardiovascular disease, infections, and osteoporosis. Nurses play an integral role in preventing and managing these complications. Cardiovascular health is a particular concern, as patients with SLE have a higher risk of developing heart disease. Nurses should monitor patients for signs of hypertension, hyperlipidemia, and other cardiovascular risk factors, encouraging regular physical activity and a heart-healthy diet. In addition to cardiovascular risks, the use of immunosuppressive medications can increase susceptibility to infections. Nurses must educate patients on the signs and symptoms of infection, promote

hand hygiene, and encourage timely vaccination (excluding live vaccines in immunocompromised patients) to prevent illness. Furthermore, long-term use of glucocorticoids, commonly prescribed to manage SLE symptoms, increases the risk of osteoporosis. Nurses should promote calcium and vitamin D supplementation, weight-bearing exercises, and regular bone density screenings to minimize bone loss and fracture risk.

### **Promoting Medication Safety**

Given the complexity of SLE treatment, medication safety is a key nursing responsibility. Nurses must monitor for side effects associated with commonly used medications, such as hydroxychloroquine, glucocorticoids, and immunosuppressive drugs. Hydroxychloroquine, while effective in controlling disease activity, can cause retinal toxicity, requiring regular ophthalmologic examinations. Nurses should educate patients on the signs of potential ocular issues, such as blurred vision or difficulty seeing at night, and the importance of reporting these symptoms promptly. Corticosteroids, another mainstay of SLE treatment, can cause a range of side effects, including weight gain, mood changes, and elevated blood glucose levels. Nurses should regularly assess for these side effects and offer strategies for managing them, such as dietary modifications or adjusting the timing of medication administration. Additionally, immunosuppressive medications can cause hematological and hepatic side effects. Nurses should monitor for abnormal blood counts or signs of liver dysfunction, such as jaundice, and ensure patients adhere to routine laboratory testing to detect these complications early.

### **Enhancing Coping and Stress Management**

Chronic illness often results in significant stress, which can exacerbate symptoms of SLE. Nurses should support patients in managing stress by teaching stress-reduction techniques such as mindfulness, meditation, and deep breathing exercises. These techniques have been shown to reduce symptoms of anxiety and improve overall well-being. Nurses should also encourage patients to engage in social support systems, including family involvement in care. Providing emotional support and fostering a sense of community can alleviate feelings of isolation and improve coping strategies. Additionally, nurses can help patients set realistic goals and expectations regarding their illness, thereby reducing anxiety and promoting a more positive outlook on disease management.

### **Collaboration with Interdisciplinary Teams**

The management of SLE requires a team approach, and nurses are essential in coordinating care among interdisciplinary team members. Nurses should collaborate with rheumatologists to ensure that treatment plans are adjusted based on disease activity and laboratory findings. In addition, dietitians can help develop nutrition plans tailored to the patient's needs, such as managing weight or addressing nutrient deficiencies associated with long-term medication use. Physical therapists may assist in maintaining mobility and improving quality of life, while occupational therapists can help patients adapt to limitations caused by joint pain or fatigue. Effective communication and collaboration with these

professionals ensure that patients receive comprehensive, holistic care that addresses all aspects of their condition. Nursing interventions for patients with SLE are multifaceted, involving education, symptom management, psychosocial support, prevention of complications, and collaboration with interdisciplinary teams. Nurses play a crucial role in improving patient outcomes by empowering patients to manage their condition and preventing complications through early intervention and ongoing monitoring. With a focus on both the physical and emotional needs of the patient, nursing care helps enhance the quality of life for individuals living with SLE, ensuring that they can manage their disease and maintain functional independence. By providing individualized care, nurses contribute significantly to the overall well-being of SLE patients.

## **Conclusion**

Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder with complex interactions between genetic, environmental, and immunological factors. Recent advancements in understanding the disease's underlying mechanisms have significantly improved our knowledge of its pathogenesis, which involves the dysregulation of both innate and adaptive immune systems. Key drivers of disease progression include the overactivation of B and T lymphocytes, particularly through autoantibodies such as anti-dsDNA and anti-ENA, and the crucial role of type-I interferons in sustaining inflammation. Additionally, defects in mitochondrial function and the accumulation of apoptotic cells exacerbate immune responses, contributing to tissue damage. This highlights the significance of a dysregulated immune tolerance mechanism in SLE, which allows the survival and activation of autoreactive cells that target self-antigens. The epidemiology of SLE has revealed its higher prevalence in women, particularly those of African, Hispanic, and Asian descent, with significant geographical variations in incidence. Mortality risk is notably higher in SLE patients due to complications like renal failure, infections, and cardiovascular events. The diagnostic process, though challenging due to the multisystem nature of the disease, has benefited from refined classification criteria and the development of specific biomarkers such as anti-dsDNA and anti-ENA antibodies. These biomarkers not only aid in diagnosis but also serve as indicators of disease activity, providing valuable insights into patient prognosis. Treatment strategies for SLE have evolved from nonspecific immunosuppressive agents to the introduction of targeted therapies that focus on specific immune pathways. Drugs such as belimumab, which targets B cell-activating factor (BAFF), have shown promise in reducing disease activity and improving patient outcomes. However, these therapies are often used in combination with traditional treatments to achieve optimal disease control. Despite these advances, there is still a need for personalized treatment approaches, as individual responses to therapy vary significantly. This underscores the importance of a tailored treatment plan based on patient-specific factors such as genetic predisposition and disease manifestations. In conclusion, while significant progress has been made in understanding and managing SLE, further research is required to develop even more effective, personalized therapeutic options. Continued exploration of immune pathways, alongside improvements in diagnostic techniques and patient stratification, will be crucial in addressing the remaining challenges in SLE management. Advances in personalized medicine hold promise for reducing the

reliance on broad immunosuppressive treatments, thus enhancing the quality of life for SLE patients and improving long-term outcomes.

## References

1. Fava, A.; Petri, M. Systemic lupus erythematosus: Diagnosis and clinical management. *J. Autoimmun.* **2019**, *96*, 1–13.
2. Justiz Vaillant, A.A.; Goyal, A.; Varacallo, M. Systemic Lupus Erythematosus. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, 2022.
3. Barrat, F.J.; Crow, M.K.; Ivashkiv, L.B. Interferon target-gene expression and epigenomic signatures in health and disease. *Nat. Immunol.* **2019**, *20*, 1574–1583.
4. Fanouriakis, A.; Kostopoulou, M.; Alunno, A.; Aringer, M.; Bajema, I.; Boletis, J.N.; Cervera, R.; Doria, A.; Gordon, C.; Govoni, M.; et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann. Rheum. Dis.* **2019**, *78*, 736–745
5. Fanouriakis, A.; Tziolos, N.; Bertias, G.; Boumpas, D.T. Update omicronn the diagnosis and management of systemic lupus erythematosus. *Ann. Rheum. Dis.* **2021**, *80*, 14–25.
6. Rees, F.; Doherty, M.; Grainge, M.J.; Lanyon, P.; Zhang, W. The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. *Rheumatology* **2017**, *56*, 1945–1961.
7. Niewold, T.B. Advances in lupus genetics. *Curr. Opin. Rheumatol.* **2015**, *27*, 440–447.
8. Salgado-Galicia, N.A.; Hernandez-Dono, S.; Ruiz-Gomez, D.; Jakez-Ocampo, J.; Zuniga, J.; Vargas-Alarcon, G.; Acuna, V.; Hernandez, M.T.; Marquez-Garcia, J.E.; Garcia-Lechuga, M.; et al. The role of socioeconomic status in the susceptibility to develop systemic lupus erythematosus in Mexican patients. *Clin. Rheumatol.* **2020**, *39*, 2151–2161.
9. Danchenko, N.; Satia, J.A.; Anthony, M.S. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. *Lupus* **2006**, *15*, 308–318.
10. Stojan, G.; Petri, M. Epidemiology of systemic lupus erythematosus: An update. *Curr. Opin. Rheumatol.* **2018**, *30*, 144–150.
11. Ocampo-Piraquive, V.; Nieto-Aristizabal, I.; Canas, C.A.; Tobon, G.J. Mortality in systemic lupus erythematosus: Causes, predictors and interventions. *Expert Rev. Clin. Immunol.* **2018**, *14*, 1043–1053.
12. Lee, Y.H.; Choi, S.J.; Ji, J.D.; Song, G.G. Overall and cause-specific mortality in systemic lupus erythematosus: An updated meta-analysis. *Lupus* **2016**, *25*, 727–734.
13. Gauderon, A.; Roux-Lombard, P.; Spoerl, D. Antinuclear Antibodies With a Homogeneous and Speckled Immunofluorescence Pattern Are Associated With Lack of Cancer While Those With a Nucleolar Pattern With the Presence of Cancer. *Front. Med.* **2020**, *7*, 165
14. Applbaum, E.; Lichtbroun, A. Novel Sjogren's autoantibodies found in fibromyalgia patients with sicca and/or xerostomia. *Autoimmun. Rev.* **2019**, *18*, 199–202.
15. Lawrence, J.M., 3rd; Moore, T.L.; Osborn, T.G.; Nesher, G.; Madson, K.L.; Kinsella, M.B. Autoantibody studies in juvenile rheumatoid arthritis. *Semin. Arthritis Rheum.* **1993**, *22*, 265–274.

16. Pisetsky, D.S.; Lipsky, P.E. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. *Nat. Rev. Rheumatol.* **2020**, *16*, 565–579.
17. Petri, M.A.; van Vollenhoven, R.F.; Buyon, J.; Levy, R.A.; Navarra, S.V.; Cervera, R.; Zhong, Z.J.; Freimuth, W.W.; Bliss, G.P.; Groups, B.-S. Baseline predictors of systemic lupus erythematosus flares: Data from the combined placebo groups in the phase III belimumab trials. *Arthritis Rheum.* **2013**, *65*, 2143–2153.
18. Negoro, N.; Kanayama, Y.; Takeda, T.; Amatsu, K.; Koda, S.; Inoue, Y.; Kim, T.; Okamura, M.; Inoue, T. Clinical significance of U1-RNP immune complexes in mixed connective tissue disease and systemic lupus erythematosus. *Rheumatol. Int.* **1987**, *7*, 7–11.
19. Novak, G.V.; Marques, M.; Balbi, V.; Gormezano, N.W.; Kozu, K.; Sakamoto, A.P.; Pereira, R.M.; Terreri, M.T.; Magalhaes, C.S.; Guariento, A.; et al. Anti-RO/SSA and anti-La/SSB antibodies: Association with mild lupus manifestations in 645 childhood-onset systemic lupus erythematosus. *Autoimmun. Rev.* **2017**, *16*, 132–135.
20. Ramirez, G.A.; Canti, V.; Del Rosso, S.; Erra, R.; Moiola, L.; Magnoni, M.; Bozzolo, E.P.; Manfredi, A.A.; Rovere-Querini, P. Diagnostic performance of aPS/PT antibodies in neuropsychiatric lupus and cardiovascular complications of systemic lupus erythematosus. *Autoimmunity* **2020**, *53*, 21–27.
21. Unlu, O.; Zuily, S.; Erkan, D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. *Eur. J. Rheumatol.* **2016**, *3*, 75–84.
22. Aringer, M.; Costenbader, K.; Daikh, D.; Brinks, R.; Mosca, M.; Ramsey-Goldman, R.; Smolen, J.S.; Wofsy, D.; Boumpas, D.T.; Kamen, D.L.; et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann. Rheum. Dis.* **2019**, *78*, 1151–1159.
23. Mikdashi, J.; Nived, O. Measuring disease activity in adults with systemic lupus erythematosus: The challenges of administrative burden and responsiveness to patient concerns in clinical research. *Arthritis Res. Ther.* **2015**, *17*, 183.
24. Gladman, D.D.; Ibanez, D.; Urowitz, M.B. Systemic lupus erythematosus disease activity index 2000. *J. Rheumatol.* **2002**, *29*, 288–291.
25. Isenberg, D.A.; Rahman, A.; Allen, E.; Farewell, V.; Akil, M.; Bruce, I.N.; D’Cruz, D.; Griffiths, B.; Khamashta, M.; Maddison, P.; et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. *Rheumatology* **2005**, *44*, 902–906.
26. Gladman, D.; Ginzler, E.; Goldsmith, C.; Fortin, P.; Liang, M.; Urowitz, M.; Bacon, P.; Bombardieri, S.; Hanly, J.; Hay, E.; et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. *Arthritis Rheum.* **1996**, *39*, 363–369.
27. Luijten, K.M.; Tekstra, J.; Bijlsma, J.W.; Bijl, M. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. *Autoimmun. Rev.* **2012**, *11*, 326–329.

28. Robinson, R. Distinct B cell receptor functions are determined by phosphorylation. *PLoS Biol.* **2006**, *4*, e231.
29. Nemazee, D. Mechanisms of central tolerance for B cells. *Nat. Rev. Immunol.* **2017**, *17*, 281–294.
30. Zikherman, J.; Parameswaran, R.; Weiss, A. Endogenous antigen tunes the responsiveness of naive B cells but not T cells. *Nature* **2012**, *489*, 160–164.
31. Burnett, D.L.; Langley, D.B.; Schofield, P.; Hermes, J.R.; Chan, T.D.; Jackson, J.; Bourne, K.; Reed, J.H.; Patterson, K.; Porebski, B.T.; et al. Germinal center antibody mutation trajectories are determined by rapid self/foreign discrimination. *Science* **2018**, *360*, 223–226.
32. Mackay, F.; Schneider, P. Cracking the BAFF code. *Nat. Rev. Immunol.* **2009**, *9*, 491–502.
33. Jackson, S.W.; Davidson, A. BAFF inhibition in SLE-Is tolerance restored? *Immunol. Rev.* **2019**, *292*, 102–119.
34. Christensen, S.R.; Shupe, J.; Nickerson, K.; Kashgarian, M.; Flavell, R.A.; Shlomchik, M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. *Immunity* **2006**, *25*, 417–428.
35. Berland, R.; Fernandez, L.; Kari, E.; Han, J.H.; Lomakin, I.; Akira, S.; Wortis, H.H.; Kearney, J.F.; Ucci, A.A.; Imanishi-Kari, T. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. *Immunity* **2006**, *25*, 429–440.
36. Christensen, S.R.; Kashgarian, M.; Alexopoulou, L.; Flavell, R.A.; Akira, S.; Shlomchik, M.J. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. *J. Exp. Med.* **2005**, *202*, 321–331.
37. Lartigue, A.; Courville, P.; Auquit, I.; Francois, A.; Arnoult, C.; Tron, F.; Gilbert, D.; Musette, P. Role of TLR9 in anti-nucleosome and anti-DNA antibody production in *lpr* mutation-induced murine lupus. *J. Immunol.* **2006**, *177*, 1349–1354.
38. Nutt, S.L.; Hodgkin, P.D.; Tarlinton, D.M.; Corcoran, L.M. The generation of antibody-secreting plasma cells. *Nat. Rev. Immunol.* **2015**, *15*, 160–171.
39. Vinuesa, C.G.; Sanz, I.; Cook, M.C. Dysregulation of germinal centres in autoimmune disease. *Nat. Rev. Immunol.* **2009**, *9*, 845–857.
40. Chan, O.; Shlomchik, M.J. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-*lpr/lpr* mice. *J. Immunol.* **1998**, *160*, 51–59.
41. Chan, O.T.; Hannum, L.G.; Haberman, A.M.; Madaio, M.P.; Shlomchik, M.J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. *J. Exp. Med.* **1999**, *189*, 1639–1648.
42. Koffler, D.; Schur, P.H.; Kunkel, H.G. Immunological studies concerning the nephritis of systemic lupus erythematosus. *J. Exp. Med.* **1967**, *126*, 607–624.
43. Ehrenstein, M.R.; Katz, D.R.; Griffiths, M.H.; Papadaki, L.; Winkler, T.H.; Kalden, J.R.; Isenberg, D.A. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. *Kidney Int.* **1995**, *48*, 705–711.
44. Mannik, M.; Merrill, C.E.; Stamps, L.D.; Wener, M.H. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. *J. Rheumatol.* **2003**, *30*, 1495–1504.
45. Izmirly, P.M.; Rivera, T.L.; Buyon, J.P. Neonatal lupus syndromes. *Rheum. Dis. Clin. N. Am.* **2007**, *33*, 267–285.

46. Shah, D.; Kiran, R.; Wanchu, A.; Bhatnagar, A. Oxidative stress in systemic lupus erythematosus: Relationship to Th1 cytokine and disease activity. *Immunol. Lett.* **2010**, *129*, 7–12.
47. Sugimoto, K.; Morimoto, S.; Kaneko, H.; Nozawa, K.; Tokano, Y.; Takasaki, Y.; Hashimoto, H. Decreased IL-4 producing CD4+ T cells in patients with active systemic lupus erythematosus—relation to IL-12R expression. *Autoimmunity* **2002**, *35*, 381–387
48. Paroli, M.; Caccavale, R.; Fiorillo, M.T.; Spadea, L.; Gumina, S.; Candela, V.; Paroli, M.P. The Double Game Played by Th17 Cells in Infection: Host Defense and Immunopathology. *Pathogens* **2022**, *11*, 1547.
49. Lopez, P.; Rodriguez-Carrio, J.; Caminal-Montero, L.; Mozo, L.; Suarez, A. A pathogenic IFN $\alpha$ , BLYS and IL-17 axis in Systemic Lupus Erythematosus patients. *Sci. Rep.* **2016**, *6*, 20651.
50. Zickert, A.; Amoudruz, P.; Sundstrom, Y.; Ronnelid, J.; Malmstrom, V.; Gunnarsson, I. IL-17 and IL-23 in lupus nephritis—association to histopathology and response to treatment. *BMC Immunol.* **2015**, *16*, 7.
51. Bonelli, M.; Savitskaya, A.; von Dalwigk, K.; Steiner, C.W.; Aletaha, D.; Smolen, J.S.; Scheinecker, C. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). *Int. Immunol.* **2008**, *20*, 861–868.
52. Alexander, T.; Sattler, A.; Templin, L.; Kohler, S.; Gross, C.; Meisel, A.; Sawitzki, B.; Burmester, G.R.; Arnold, R.; Radbruch, A.; et al. Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. *Ann. Rheum. Dis.* **2013**, *72*, 1549–1558.
53. La Cava, A. Tregs in SLE: An Update. *Curr. Rheumatol. Rep.* **2018**, *20*, 6.
54. Chen, P.M.; Tsokos, G.C. T Cell Abnormalities in the Pathogenesis of Systemic Lupus Erythematosus: An Update. *Curr. Rheumatol. Rep.* **2021**, *23*, 12.
55. Liarski, V.M.; Kaverina, N.; Chang, A.; Brandt, D.; Yanez, D.; Talasnik, L.; Carlesso, G.; Herbst, R.; Utset, T.O.; Labno, C.; et al. Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue. *Sci. Transl. Med.* **2014**, *6*, 230ra246.
56. Comte, D.; Karampetsou, M.P.; Yoshida, N.; Kis-Toth, K.; Kyttaris, V.C.; Tsokos, G.C. Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus. *Arthritis Rheumatol.* **2017**, *69*, 1035–1044.
57. McKinney, E.F.; Lee, J.C.; Jayne, D.R.; Lyons, P.A.; Smith, K.G. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. *Nature* **2015**, *523*, 612–616.
58. Katsuyama, E.; Suarez-Fueyo, A.; Bradley, S.J.; Mizui, M.; Marin, A.V.; Mulki, L.; Krishfield, S.; Malavasi, F.; Yoon, J.; Sui, S.J.H.; et al. The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections. *Cell Rep.* **2020**, *30*, 112–123.e114.
59. Li, X.; Kang, N.; Zhang, X.; Dong, X.; Wei, W.; Cui, L.; Ba, D.; He, W. Generation of human regulatory gammadelta T cells by TCRgammadelta stimulation in the presence of TGF- $\beta$  and their involvement in the pathogenesis of systemic lupus erythematosus. *J. Immunol.* **2011**, *186*, 6693–6700.
60. Robak, E.; Niewiadomska, H.; Robak, T.; Bartkowiak, J.; Blonski, J.Z.; Wozniacka, A.; Pomorski, L.; Sysa-Jedrezejowska, A. Lymphocytes

- Tgammadelta in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity. *Mediat. Inflamm.* **2001**, *10*, 179–189.
61. Brandt, L.; Hedberg, H. Impaired phagocytosis by peripheral blood granulocytes in systemic lupus erythematosus. *Scand. J. Haematol.* **1969**, *6*, 348–353.
  62. Donnelly, S.; Roake, W.; Brown, S.; Young, P.; Naik, H.; Wordsworth, P.; Isenberg, D.A.; Reid, K.B.; Eggleton, P. Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. *Arthritis Rheum.* **2006**, *54*, 1543–1556.
  63. Lood, C.; Blanco, L.P.; Purmalek, M.M.; Carmona-Rivera, C.; De Ravin, S.S.; Smith, C.K.; Malech, H.L.; Ledbetter, J.A.; Elkon, K.B.; Kaplan, M.J. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. *Nat. Med.* **2016**, *22*, 146–153.
  64. Hom, G.; Graham, R.R.; Modrek, B.; Taylor, K.E.; Ortmann, W.; Garnier, S.; Lee, A.T.; Chung, S.A.; Ferreira, R.C.; Pant, P.V.; et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. *N. Engl. J. Med.* **2008**, *358*, 900–909.
  65. Olsson, L.M.; Johansson, A.C.; Gullstrand, B.; Jonsen, A.; Saevarsdottir, S.; Ronnblom, L.; Leonard, D.; Wettero, J.; Sjowall, C.; Svenungsson, E.; et al. A single nucleotide polymorphism in the NCF1 gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. *Ann. Rheum. Dis.* **2017**, *76*, 1607–1613.
  66. Jacob, C.O.; Eisenstein, M.; Dinauer, M.C.; Ming, W.; Liu, Q.; John, S.; Quismorio, F.P., Jr.; Reiff, A.; Myones, B.L.; Kaufman, K.M.; et al. Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, E59–E67
  67. Lindau, D.; Mussard, J.; Rabsteyn, A.; Ribon, M.; Kotter, I.; Igney, A.; Adema, G.J.; Boissier, M.C.; Rammensee, H.G.; Decker, P. TLR9 independent interferon alpha production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen. *Ann. Rheum. Dis.* **2014**, *73*, 2199–2207.
  68. Palanichamy, A.; Bauer, J.W.; Yalavarthi, S.; Meednu, N.; Barnard, J.; Owen, T.; Cistrone, C.; Bird, A.; Rabinovich, A.; Nevarez, S.; et al. Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. *J. Immunol.* **2014**, *192*, 906–918.
  69. Rahman, S.; Sagar, D.; Hanna, R.N.; Lightfoot, Y.L.; Mistry, P.; Smith, C.K.; Manna, Z.; Hasni, S.; Siegel, R.M.; Sanjuan, M.A.; et al. Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. *Ann. Rheum. Dis.* **2019**, *78*, 957–966.
  70. Midgley, A.; Beresford, M.W. Increased expression of low density granulocytes in juvenile-onset systemic lupus erythematosus patients correlates with disease activity. *Lupus* **2016**, *25*, 407–411.
  71. Denny, M.F.; Yalavarthi, S.; Zhao, W.; Thacker, S.G.; Anderson, M.; Sandy, A.R.; McCune, W.J.; Kaplan, M.J. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces

- vascular damage and synthesizes type I IFNs. *J. Immunol.* **2010**, *184*, 3284–3297.
72. Boeltz, S.; Amini, P.; Anders, H.J.; Andrade, F.; Bilyy, R.; Chatfield, S.; Cichon, I.; Clancy, D.M.; Desai, J.; Dumych, T.; et al. To NET or not to NET: current opinions and state of the science regarding the formation of neutrophil extracellular traps. *Cell Death Differ.* **2019**, *26*, 395–408.
73. Apel, F.; Zychlinsky, A.; Kenny, E.F. The role of neutrophil extracellular traps in rheumatic diseases. *Nat. Rev. Rheumatol.* **2018**, *14*, 467–475.
74. Odqvist, L.; Jevnikar, Z.; Riise, R.; Oberg, L.; Rhedin, M.; Leonard, D.; Yrlid, L.; Jackson, S.; Mattsson, J.; Nanda, S.; et al. Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. *Ann. Rheum. Dis.* **2019**, *78*, 1363–1370.
75. Chang, H.H.; Dwivedi, N.; Nicholas, A.P.; Ho, I.C. The W620 Polymorphism in PTPN22 Disrupts Its Interaction With Peptidylarginine Deiminase Type 4 and Enhances Citrullination and NETosis. *Arthritis Rheumatol.* **2015**, *67*, 2323–2334.
76. Li, D.; Matta, B.; Song, S.; Nelson, V.; Diggins, K.; Simpfendorfer, K.R.; Gregersen, P.K.; Linsley, P.; Barnes, B.J. IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE. *JCI Insight* **2020**, *5*, e124020.
77. Goel, R.R.; Nakabo, S.; Dizon, B.L.P.; Urban, A.; Waldman, M.; Howard, L.; Darnell, D.; Buhaya, M.; Carmona-Rivera, C.; Hasni, S.; et al. Lupus-like autoimmunity and increased interferon response in patients with STAT3-deficient hyper-IgE syndrome. *J. Allergy Clin. Immunol.* **2021**, *147*, 746–749.e9.
78. Kahlenberg, J.M.; Carmona-Rivera, C.; Smith, C.K.; Kaplan, M.J. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. *J. Immunol.* **2013**, *190*, 1217–1226.
79. Sisirak, V.; Ganguly, D.; Lewis, K.L.; Couillault, C.; Tanaka, L.; Bolland, S.; D'Agati, V.; Elkon, K.B.; Reizis, B. Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus. *J. Exp. Med.* **2014**, *211*, 1969–1976.
80. Fiore, N.; Castellano, G.; Blasi, A.; Capobianco, C.; Loverre, A.; Montinaro, V.; Netti, S.; Torres, D.; Manno, C.; Grandaliano, G.; et al. Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. *Mol. Immunol.* **2008**, *45*, 259–265.
81. Sakata, K.; Nakayamada, S.; Miyazaki, Y.; Kubo, S.; Ishii, A.; Nakano, K.; Tanaka, Y. Up-Regulation of TLR7-Mediated IFN- $\alpha$  Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus. *Front. Immunol.* **2018**, *9*, 1957.
82. Bave, U.; Magnusson, M.; Eloranta, M.L.; Perers, A.; Alm, G.V.; Ronnblom, L. Fc  $\gamma$ RIIIa is expressed on natural IFN- $\alpha$ -producing cells (plasmacytoid dendritic cells) and is required for the IFN- $\alpha$  production induced by apoptotic cells combined with lupus IgG. *J. Immunol.* **2003**, *171*, 3296–3302.
83. Garcia-Romo, G.S.; Caielli, S.; Vega, B.; Connolly, J.; Allantaz, F.; Xu, Z.; Punaro, M.; Baisch, J.; Guiducci, C.; Coffman, R.L.; et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. *Sci. Transl. Med.* **2011**, *3*, 73ra20.

84. Hjorton, K.; The DISSECT consortium; Hagberg, N.; Israelsson, E.; Jinton, L.; Berggren, O.; Sandling, J.K.; Thörn, K.; Mo, J.; Eloranta, M.-L.; et al. Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor. *Arthritis Res. Ther.* **2018**, *20*, 238.
85. Corzo, C.A.; Varfolomeev, E.; Setiadi, A.F.; Francis, R.; Klabunde, S.; Senger, K.; Sujatha-Bhaskar, S.; Drobnick, J.; Do, S.; Suto, E.; et al. The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells. *Sci. Signal.* **2020**, *13*, eaaz1053.
86. Swiecki, M.; Colonna, M. The multifaceted biology of plasmacytoid dendritic cells. *Nat. Rev. Immunol.* **2015**, *15*, 471–485.
87. Jego, G.; Palucka, A.K.; Blanck, J.P.; Chalouni, C.; Pascual, V.; Banchereau, J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. *Immunity* **2003**, *19*, 225–234.
88. Soni, C.; Perez, O.A.; Voss, W.N.; Pucella, J.N.; Serpas, L.; Mehl, J.; Ching, K.L.; Goike, J.; Georgiou, G.; Ippolito, G.C.; et al. Plasmacytoid Dendritic Cells and Type I Interferon Promote Extrafollicular B Cell Responses to Extracellular Self-DNA. *Immunity* **2020**, *52*, 1022–1038.e1027.
89. Clement, M.; Charles, N.; Escoubet, B.; Guedj, K.; Chauveheid, M.P.; Caligiuri, G.; Nicoletti, A.; Papo, T.; Sacre, K. CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus. *J. Autoimmun.* **2015**, *63*, 59–67.
90. Ito, T.; Yang, M.; Wang, Y.H.; Lande, R.; Gregorio, J.; Perng, O.A.; Qin, X.F.; Liu, Y.J.; Gilliet, M. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. *J. Exp. Med.* **2007**, *204*, 105–115.
91. Jahrsdorfer, B.; Vollmer, A.; Blackwell, S.E.; Maier, J.; Sontheimer, K.; Beyer, T.; Mandel, B.; Lunov, O.; Tron, K.; Nienhaus, G.U.; et al. Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. *Blood* **2010**, *115*, 1156–1165.
92. Moseman, E.A.; Liang, X.; Dawson, A.J.; Panoskaltzis-Mortari, A.; Krieg, A.M.; Liu, Y.J.; Blazar, B.R.; Chen, W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. *J. Immunol.* **2004**, *173*, 4433–4442.
93. Menon, M.; Blair, P.A.; Isenberg, D.A.; Mauri, C. A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus. *Immunity* **2016**, *44*, 683–697.
94. Abrahams, J.P.; Leslie, A.G.; Lutter, R.; Walker, J.E. Structure at 2.8 Å resolution of F1-ATPase from bovine heart mitochondria. *Nature* **1994**, *370*, 621–628.
95. Alam, K.; Moinuddin; Jabeen, S. Immunogenicity of mitochondrial DNA modified by hydroxyl radical. *Cell. Immunol.* **2007**, *247*, 12–17.
96. Chen, L.; Duvvuri, B.; Grigull, J.; Jamnik, R.; Wither, J.E.; Wu, G.E. Experimental evidence that mutated-self peptides derived from mitochondrial DNA somatic mutations have the potential to trigger autoimmunity. *Hum. Immunol.* **2014**, *75*, 873–879.
97. Lopez-Lopez, L.; Nieves-Plaza, M.; Castro Mdel, R.; Font, Y.M.; Torres-Ramos, C.A.; Vila, L.M.; Ayala-Pena, S. Mitochondrial DNA damage is associated with damage accrual and disease duration in patients with systemic lupus erythematosus. *Lupus* **2014**, *23*, 1133–1141.

98. Zhang, Q.; Raof, M.; Chen, Y.; Sumi, Y.; Sursal, T.; Junger, W.; Brohi, K.; Itagaki, K.; Hauser, C.J. Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature* **2010**, *464*, 104–107.
99. Vyshkina, T.; Sylvester, A.; Sadiq, S.; Bonilla, E.; Canter, J.A.; Perl, A.; Kalman, B. Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus. *Clin. Immunol.* **2008**, *129*, 31–35.
100. Jonsen, A.; Yu, X.; Truedsson, L.; Nived, O.; Sturfelt, G.; Ibrahim, S.; Bengtsson, A. Mitochondrial DNA polymorphisms are associated with susceptibility and phenotype of systemic lupus erythematosus. *Lupus* **2009**, *18*, 309–312.
101. Tang, Y.; Wang, L.; Zhu, M.; Yang, M.; Zhong, K.; Du, Q.; Zhang, H.; Gui, M. Association of mtDNA M/N haplogroups with systemic lupus erythematosus: A case-control study of Han Chinese women. *Sci. Rep.* **2015**, *5*, 10817.
102. Yu, X.; Wester-Rosenlof, L.; Gimsa, U.; Holzhueter, S.A.; Marques, A.; Jonas, L.; Hagenow, K.; Kunz, M.; Nizze, H.; Tiedge, M.; et al. The mtDNA nt7778 G/T polymorphism affects autoimmune diseases and reproductive performance in the mouse. *Hum. Mol. Genet.* **2009**, *18*, 4689–4698.
103. Caielli, S.; Athale, S.; Domic, B.; Murat, E.; Chandra, M.; Banchereau, R.; Baisch, J.; Phelps, K.; Clayton, S.; Gong, M.; et al. Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus. *J. Exp. Med.* **2016**, *213*, 697–713.
104. Becker, Y.; Marcoux, G.; Allaey, I.; Julien, A.S.; Loignon, R.C.; Benk-Fortin, H.; Rollet-Labelle, E.; Rauch, J.; Fortin, P.R.; Boilard, E. Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA. *Front. Immunol.* **2019**, *10*, 1026.
105. Sisirak, V.; Sally, B.; D’Agati, V.; Martinez-Ortiz, W.; Ozcakar, Z.B.; David, J.; Rashidfarrokhi, A.; Yeste, A.; Panea, C.; Chida, A.S.; et al. Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. *Cell* **2016**, *166*, 88–101.
106. Al-Mayouf, S.M.; Sunker, A.; Abdwani, R.; Arawi, S.A.; Almurshedi, F.; Alhashmi, N.; Al Sonbul, A.; Sewairi, W.; Qari, A.; Abdallah, E.; et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. *Nat. Genet.* **2011**, *43*, 1186–1188.
107. Hartl, J.; Serpas, L.; Wang, Y.; Rashidfarrokhi, A.; Perez, O.A.; Sally, B.; Sisirak, V.; Soni, C.; Khodadadi-Jamayran, A.; Tsirigos, A.; et al. Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. *J. Exp. Med.* **2021**, *218*, e20201138.
108. Kawane, K.; Fukuyama, H.; Kondoh, G.; Takeda, J.; Ohsawa, Y.; Uchiyama, Y.; Nagata, S. Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver. *Science* **2001**, *292*, 1546–1549.
109. Yoshida, H.; Okabe, Y.; Kawane, K.; Fukuyama, H.; Nagata, S. Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. *Nat. Immunol.* **2005**, *6*, 49–56.
110. Grieves, J.L.; Fye, J.M.; Harvey, S.; Grayson, J.M.; Hollis, T.; Perrino, F.W. Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 5117–5122.
111. Crow, Y.J.; Hayward, B.E.; Parmar, R.; Robins, P.; Leitch, A.; Ali, M.; Black, D.N.; van Bokhoven, H.; Brunner, H.G.; Hamel, B.C.; et al. Mutations in the

- gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. *Nat. Genet.* **2006**, *38*, 917–920.
112. Shinde, R.; Hezaveh, K.; Halaby, M.J.; Kloetgen, A.; Chakravarthy, A.; da Silva Medina, T.; Deol, R.; Manion, K.P.; Baglaenko, Y.; Eldh, M.; et al. Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans. *Nat. Immunol.* **2018**, *19*, 571–582.
  113. Ravishankar, B.; Liu, H.; Shinde, R.; Chandler, P.; Baban, B.; Tanaka, M.; Munn, D.H.; Mellor, A.L.; Karlsson, M.C.; McGaha, T.L. Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 3909–3914.
  114. Ravishankar, B.; Liu, H.; Shinde, R.; Chaudhary, K.; Xiao, W.; Bradley, J.; Koritzinsky, M.; Madaio, M.P.; McGaha, T.L. The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 10774–10779.
  115. Vaux, D.L.; Flavell, R.A. Apoptosis genes and autoimmunity. *Curr. Opin. Immunol.* **2000**, *12*, 719–724.
  116. Henson, P.M.; Hume, D.A. Apoptotic cell removal in development and tissue homeostasis. *Trends Immunol.* **2006**, *27*, 244–250.
  117. Devitt, A.; Parker, K.G.; Ogden, C.A.; Oldreive, C.; Clay, M.F.; Melville, L.A.; Bellamy, C.O.; Lacy-Hulbert, A.; Gangloff, S.C.; Goyert, S.M.; et al. Persistence of apoptotic cells without autoimmune disease or inflammation in CD14<sup>-/-</sup> mice. *J. Cell Biol.* **2004**, *167*, 1161–1170.
  118. Lande, R.; Ganguly, D.; Facchinetti, V.; Frasca, L.; Conrad, C.; Gregorio, J.; Meller, S.; Chamilos, G.; Sebasigari, R.; Ricciari, V.; et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. *Sci. Transl. Med.* **2011**, *3*, 73ra19.
  119. Crow, M.K.; Wohlgemuth, J. Microarray analysis of gene expression in lupus. *Arthritis Res. Ther.* **2003**, *5*, 279–287.
  120. Ivashkiv, L.B. IFN $\gamma$ : Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. *Nat. Rev. Immunol.* **2018**, *18*, 545–558.
  121. Lee, S.; Baldrige, M.T. Interferon-Lambda: A Potent Regulator of Intestinal Viral Infections. *Front. Immunol.* **2017**, *8*, 749. [
  122. Ivashkiv, L.B.; Donlin, L.T. Regulation of type I interferon responses. *Nat. Rev. Immunol.* **2014**, *14*, 36–49.
  123. Chyuan, I.T.; Tzeng, H.T.; Chen, J.Y. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus. *Cells* **2019**, *8*, 963.
  124. Liu, Y.J. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. *Annu. Rev. Immunol.* **2005**, *23*, 275–306.
  125. Petro, T.M. IFN Regulatory Factor 3 in Health and Disease. *J. Immunol.* **2020**, *205*, 1981–1989.
  126. Siegal, F.P.; Kadowaki, N.; Shodell, M.; Fitzgerald-Bocarsly, P.A.; Shah, K.; Ho, S.; Antonenko, S.; Liu, Y.J. The nature of the principal type 1 interferon-producing cells in human blood. *Science* **1999**, *284*, 1835–1837.
  127. Schoggins, J.W. Interferon-Stimulated Genes: What Do They All Do? *Annu. Rev. Virol.* **2019**, *6*, 567–584.

128. Stark, G.R.; Darnell, J.E., Jr. The JAK-STAT pathway at twenty. *Immunity* **2012**, *36*, 503–514.
129. Steinberg, A.D.; Baron, S.; Talal, N. The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid. *Proc. Natl. Acad. Sci. USA* **1969**, *63*, 1102–1107.
130. Okanou, T.; Sakamoto, S.; Itoh, Y.; Minami, M.; Yasui, K.; Sakamoto, M.; Nishioji, K.; Katagishi, T.; Nakagawa, Y.; Tada, H.; et al. Side effects of high-dose interferon therapy for chronic hepatitis C. *J. Hepatol.* **1996**, *25*, 283–291.
131. Gota, C.; Calabrese, L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. *Autoimmunity* **2003**, *36*, 511–518.
132. Niewold, T.B. Interferon alpha-induced lupus: Proof of principle. *J. Clin. Rheumatol.* **2008**, *14*, 131–132.
133. Niewold, T.B.; Swedler, W.I. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. *Clin. Rheumatol.* **2005**, *24*, 178–181.
134. Wilson, L.E.; Widman, D.; Dikman, S.H.; Gorevic, P.D. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. *Semin. Arthritis Rheum.* **2002**, *32*, 163–173. [
135. Graham, R.R.; Kozyrev, S.V.; Baechler, E.C.; Reddy, M.V.; Plenge, R.M.; Bauer, J.W.; Ortmann, W.A.; Koeth, T.; Gonzalez Escribano, M.F.; the Argentine and Spanish Collaborative Groups; et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. *Nat. Genet.* **2006**, *38*, 550–555.
136. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN); Harley, J.B.; Alarcon-Riquelme, M.E.; Criswell, L.A.; Jacob, C.O.; Kimberly, R.P.; Moser, K.L.; Tsao, B.P.; Vyse, T.J.; Langefeld, C.D.; et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PTK, KIAA1542 and other loci. *Nat. Genet.* **2008**, *40*, 204–210.
137. Lessard, C.J.; Adrianto, I.; Ice, J.A.; Wiley, G.B.; Kelly, J.A.; Glenn, S.B.; Adler, A.J.; Li, H.; Rasmussen, A.; Williams, A.H.; et al. Identification of IRF8, TMEM39A, and IKZF3-ZBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. *Am. J. Hum. Genet.* **2012**, *90*, 648–660.
138. Ghodke-Puranik, Y.; Niewold, T.B. Genetics of the type I interferon pathway in systemic lupus erythematosus. *Int. J. Clin. Rheumatol.* **2013**, *8*, 657–669.
139. van Vollenhoven, R.; Askanase, A.D.; Bombardieri, A.S.; Bruce, I.N.; Carroll, A.; Dall’Era, M.; Daniels, M.; Levy, R.A.; Schwarting, A.; Quasny, H.A.; et al. Conceptual framework for defining disease modification in systemic lupus erythematosus: A call for formal criteria. *Lupus Sci. Med.* **2022**, *9*, e000634.
140. van Vollenhoven, R.; Voskuyl, A.; Bertsias, G.; Aranow, C.; Aringer, M.; Arnaud, L.; Askanase, A.; Balazova, P.; Bonfa, E.; Bootsma, H.; et al. A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS). *Ann. Rheum. Dis.* **2017**, *76*, 554–561.
141. Franklyn, K.; Lau, C.S.; Navarra, S.V.; Louthrenoo, W.; Lateef, A.; Hamijoyo, L.; Wahono, C.S.; Chen, S.L.; Jin, O.; Morton, S.; et al. Definition and initial

- validation of a Lupus Low Disease Activity State (LLDAS). *Ann. Rheum. Dis.* **2016**, *75*, 1615–1621.
142. Almeida-Brasil, C.C.; Hanly, J.G.; Urowitz, M.; Clarke, A.E.; Ruiz-Irastorza, G.; Gordon, C.; Ramsey-Goldman, R.; Petri, M.; Ginzler, E.M.; Wallace, D.J.; et al. Flares after hydroxychloroquine reduction or discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. *Ann. Rheum. Dis.* **2022**, *81*, 370–378.
  143. Shinjo, S.K.; Bonfa, E.; Wojdyla, D.; Borba, E.F.; Ramirez, L.A.; Scherbarth, H.R.; Brenol, J.C.; Chacon-Diaz, R.; Neira, O.J.; Berbotto, G.A.; et al. Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin American inception cohort. *Arthritis Rheum.* **2010**, *62*, 855–862.
  144. Ruiz-Irastorza, G.; Ramos-Casals, M.; Brito-Zeron, P.; Khamashta, M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. *Ann. Rheum. Dis.* **2010**, *69*, 20–28.
  145. Ugarte-Gil, M.F.; Mak, A.; Leong, J.; Dharmadhikari, B.; Kow, N.Y.; Reategui-Sokolova, C.; Elera-Fitzcarrald, C.; Aranow, C.; Arnaud, L.; Askanase, A.D.; et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: A systematic literature review and meta-regression analysis of longitudinal observational studies. *Lupus Sci. Med.* **2021**, *8*, e000590.
  146. Anderka, M.T.; Lin, A.E.; Abuelo, D.N.; Mitchell, A.A.; Rasmussen, S.A. Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature. *Am. J. Med. Genet. A* **2009**, *149A*, 1241–1248.
  147. Houssiau, F.A.; Vasconcelos, C.; D’Cruz, D.; Sebastiani, G.D.; Garrido, E.D.R.; Danieli, M.G.; Abramovicz, D.; Blockmans, D.; Mathieu, A.; Direskeneli, H.; et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. *Arthritis Rheum.* **2002**, *46*, 2121–2131.
  148. Emadi, A.; Jones, R.J.; Brodsky, R.A. Cyclophosphamide and cancer: Golden anniversary. *Nat. Rev. Clin. Oncol.* **2009**, *6*, 638–647.
  149. Dorner, T.; Furie, R. Novel paradigms in systemic lupus erythematosus. *Lancet* **2019**, *393*, 2344–2358.
  150. Merrill, J.T.; Neuwelt, C.M.; Wallace, D.J.; Shanahan, J.C.; Latinis, K.M.; Oates, J.C.; Utset, T.O.; Gordon, C.; Isenberg, D.A.; Hsieh, H.J.; et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. *Arthritis Rheum.* **2010**, *62*, 222–233.
  151. Rovin, B.H.; Furie, R.; Latinis, K.; Looney, R.J.; Fervenza, F.C.; Sanchez-Guerrero, J.; Maciucă, R.; Zhang, D.; Garg, J.P.; Brunetta, P.; et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. *Arthritis Rheum.* **2012**, *64*, 1215–1226.
  152. Teng, Y.K.; Levarht, E.W.; Toes, R.E.; Huizinga, T.W.; van Laar, J.M. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. *Ann. Rheum. Dis.* **2009**, *68*, 1011–1016.
  153. Pijpe, J.; Meijer, J.M.; Bootsma, H.; van der Wal, J.E.; Spijkervet, F.K.; Kallenberg, C.G.; Vissink, A.; Ihrler, S. Clinical and histologic evidence of

- salivary gland restoration supports the efficacy of rituximab treatment in Sjogren's syndrome. *Arthritis Rheum.* **2009**, *60*, 3251–3256.
154. Kansal, R.; Richardson, N.; Neeli, I.; Khawaja, S.; Chamberlain, D.; Ghani, M.; Ghani, Q.U.; Balazs, L.; Beranova-Giorgianni, S.; Giorgianni, F.; et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. *Sci. Transl. Med.* **2019**, *11*, eaav1648.
155. Gomez Mendez, L.M.; Cascino, M.D.; Garg, J.; Katsumoto, T.R.; Brakeman, P.; Dall'Era, M.; Looney, R.J.; Rovin, B.; Dragone, L.; Brunetta, P. Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. *Clin. J. Am. Soc. Nephrol.* **2018**, *13*, 1502–1509.
156. Meyer, S.; Evers, M.; Jansen, J.H.M.; Buijs, J.; Broek, B.; Reitsma, S.E.; Moerer, P.; Amini, M.; Kretschmer, A.; Ten Broeke, T.; et al. New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies. *Br. J. Haematol.* **2018**, *180*, 808–820.
157. Marinov, A.D.; Wang, H.; Bastacky, S.I.; van Puijenbroek, E.; Schindler, T.; Speziale, D.; Perro, M.; Klein, C.; Nickerson, K.M.; Shlomchik, M.J. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model. *Arthritis Rheumatol.* **2021**, *73*, 826–836.
158. Mysler, E.F.; Spindler, A.J.; Guzman, R.; Bijl, M.; Jayne, D.; Furie, R.A.; Houssiau, F.A.; Drappa, J.; Close, D.; Maciuga, R.; et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. *Arthritis Rheum.* **2013**, *65*, 2368–2379.
159. Navarra, S.V.; Guzman, R.M.; Gallacher, A.E.; Hall, S.; Levy, R.A.; Jimenez, R.E.; Li, E.K.; Thomas, M.; Kim, H.Y.; Leon, M.G.; et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. *Lancet* **2011**, *377*, 721–731.
160. Furie, R.; Petri, M.; Zamani, O.; Cervera, R.; Wallace, D.J.; Tegzova, D.; Sanchez-Guerrero, J.; Schwarting, A.; Merrill, J.T.; Chatham, W.W.; et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum.* **2011**, *63*, 3918–3930.
161. van Vollenhoven, R.F.; Petri, M.A.; Cervera, R.; Roth, D.A.; Ji, B.N.; Kleoudis, C.S.; Zhong, Z.J.; Freimuth, W. Belimumab in the treatment of systemic lupus erythematosus: High disease activity predictors of response. *Ann. Rheum. Dis.* **2012**, *71*, 1343–1349.
162. Urowitz, M.B.; Ohsfeldt, R.L.; Wielage, R.C.; Kelton, K.A.; Asukai, Y.; Ramachandran, S. Organ damage in patients treated with belimumab versus standard of care: A propensity score-matched comparative analysis. *Ann. Rheum. Dis.* **2019**, *78*, 372–379.
163. Furie, R.A.; Wallace, D.J.; Aranow, C.; Fettiplace, J.; Wilson, B.; Mistry, P.; Roth, D.A.; Gordon, D. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States. *Arthritis Rheumatol.* **2018**, *70*, 868–877.
164. van Vollenhoven, R.F.; Navarra, S.V.; Levy, R.A.; Thomas, M.; Heath, A.; Lustine, T.; Adamkovic, A.; Fettiplace, J.; Wang, M.L.; Ji, B.; et al. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: A Phase III study extension. *Rheumatology* **2020**, *59*, 281–291.

165. Stohl, W.; Schwarting, A.; Okada, M.; Scheinberg, M.; Doria, A.; Hammer, A.E.; Kleoudis, C.; Groark, J.; Bass, D.; Fox, N.L.; et al. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. *Arthritis Rheumatol.* **2017**, *69*, 1016–1027.
166. Brunner, H.I.; Abud-Mendoza, C.; Viola, D.O.; Calvo Penades, I.; Levy, D.; Anton, J.; Calderon, J.E.; Chasnyk, V.G.; Ferrandiz, M.A.; Keltsev, V.; et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial. *Ann. Rheum. Dis.* **2020**, *79*, 1340–1348.
167. Furie, R.; Rovin, B.H.; Houssiau, F.; Malvar, A.; Teng, Y.K.O.; Contreras, G.; Amoura, Z.; Yu, X.; Mok, C.C.; Santiago, M.B.; et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. *N. Engl. J. Med.* **2020**, *383*, 1117–1128.
168. Rovin, B.H.; Furie, R.; Teng, Y.K.O.; Contreras, G.; Malvar, A.; Yu, X.; Ji, B.; Green, Y.; Gonzalez-Rivera, T.; Bass, D.; et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. *Kidney Int.* **2022**, *101*, 403–413.
169. Tanaka, Y.; Tummala, R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: An overview from clinical trials. *Mod. Rheumatol.* **2021**, *31*, 1–
170. Furie, R.; Khamashta, M.; Merrill, J.T.; Werth, V.P.; Kalunian, K.; Brohawn, P.; Illei, G.G.; Drappa, J.; Wang, L.; Yoo, S.; et al. Anifrolumab, an Anti-Interferon-alpha Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. *Arthritis Rheumatol.* **2017**, *69*, 376–386.
171. Furie, R.A.; Morand, E.F.; Bruce, I.N.; Manzi, S.; Kalunian, K.C.; Vital, E.M.; Ford, T.L.; Gupta, R.; Hiepe, F.; Santiago, M. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. *Lancet Rheumatol.* **2019**, *1*, e208–e219.
172. Morand, E.F.; Furie, R.; Tanaka, Y.; Bruce, I.N.; Askanase, A.D.; Richez, C.; Bae, S.C.; Brohawn, P.Z.; Pineda, L.; Berglind, A.; et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. *N. Engl. J. Med.* **2020**, *382*, 211–221.
173. Furie, R.; Morand, E.F.; Askanase, A.D.; Vital, E.M.; Merrill, J.T.; Kalyani, R.N.; Abreu, G.; Pineda, L.; Tummala, R. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. *Lupus* **2021**, *30*, 1254–1263
174. Vital, E.M.; Merrill, J.T.; Morand, E.F.; Furie, R.A.; Bruce, I.N.; Tanaka, Y.; Manzi, S.; Kalunian, K.C.; Kalyani, R.N.; Streicher, K.; et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: Post hoc analysis of pooled data from two phase III trials. *Ann. Rheum. Dis.* **2022**, *81*, 951–961.

## التعامل مع الذئبة الحمراء (SLE) وخطة التدخل التمريضي - مراجعة محدثة

### الملخص:

**الخلفية:** الذئبة الحمراء الجهازية (SLE) هي مرض مناعي ذاتي مزمن يتميز بتفاقمات دورية وانخفاضات في الأعراض، مما يؤدي إلى تلف متعدد الأعضاء. يتميز المرض بإنتاج الأجسام المضادة الذاتية التي تسبب الالتهاب وإصابة الأنسجة. وعلى الرغم من التقدم في فهم آلية تطور المرض، فإن العلاجات ما زالت تعتمد على العلاجات المناعية العامة، مع ظهور علاجات مسهدة جديدة تعد خيارات واعدة. تستعرض هذه المراجعة الآليات الكامنة وراء مرض الذئبة الحمراء وتقييم الاستراتيجيات العلاجية الحالية والمستقبلية.

**الهدف:** تهدف هذه المراجعة إلى تقديم نظرة محدثة حول آلية تطور الذئبة الحمراء، والتقدم الأخير في أساليب التشخيص، وتطور العلاجات المسهدة، مع التركيز على إمكانيات العلاج الشخصي.

**الطرق:** تجمع هذه المراجعة الأدبيات الحديثة المتعلقة بالوبائيات، وآلية تطور المرض، ومعايير التشخيص، والتقدمات العلاجية المتعلقة بالذئبة الحمراء. كما تستعرض أدوار المناعة التكيفية والفطرية، واضطراب الميتوكوندريا، والموت الخلوي المبرمج، واشتراك الإنترفيرون في تقدم المرض.

**النتائج:** تتضمن آلية تطور الذئبة الحمراء استجابة مناعية غير منظمة، مع مساهمات كبيرة من الخلايا للمفاوية B و T، وإنتاج الإنترفيرون من النوع الأول (IFN)، واضطراب في الخلايا العدلية، والاختلالات في الميتوكوندريا. وقد حسنت التقدمات في أدوات التشخيص، مثل الأجسام المضادة ضد ال dsDNA والأجسام المضادة ضد ENA، من قدرة التعرف على المرض. تشمل الاستراتيجيات العلاجية الآن العلاجات المناعية التقليدية بالإضافة إلى العلاجات المسهدة الأحدث التي تركز على مسارات مناعية محددة، بهدف تقليل الاعتماد على الأدوية المناعية العامة.

**الخلاصة:** تظل الذئبة الحمراء مرضاً معقداً ومتعدد العوامل، حيث أدى التقدم في فهم آليتها إلى ابتكارات علاجية واعدة. من المتوقع أن تحسن العلاجات المسهدة واستراتيجيات العلاج الشخصي بشكل كبير نتائج المرضى. ومع ذلك، لا تزال هناك تحديات في تحسين طرق العلاج والتعامل مع التباين في المرض عبر الفئات السكانية المختلفة.

**الكلمات المفتاحية:** الذئبة الحمراء الجهازية، المرض المناعي الذاتي، آلية تطور المرض، العلاجات المسهدة، الجهاز المناعي، الميتوكوندريا، الإنترفيرون، الخلايا B، الخلايا T، التهاب الكلى الذئبي.